丽珠医药(01513)发布公告，于2025年8月25日斥资299.92万元回购7.23万股A股股份。 ...

Group 1 - The company, Lijun Pharmaceutical (01513.HK), announced a share buyback on August 25, 2023, spending 2.9992 million yuan to repurchase 72,300 A-shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年8月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Group 1 - The core viewpoint of the news highlights the recent stock performance and financial metrics of Lizhu Group, indicating a positive trend in stock price and a slight decrease in revenue [1][2] - As of August 25, Lizhu Group's stock price increased by 2.02% to 41.85 CNY per share, with a total market capitalization of 37.837 billion CNY [1] - The company has seen a year-to-date stock price increase of 13.35%, with a 2.45% rise over the last five trading days [1] Group 2 - Lizhu Group's main business segments include chemical preparations (52.14%), raw materials and intermediates (26.49%), traditional Chinese medicine preparations (12.75%), diagnostic reagents and equipment (5.97%), and biological products (1.51%) [2] - For the first half of 2025, Lizhu Group reported operating revenue of 6.272 billion CNY, a slight decrease of 0.17% year-on-year, while net profit attributable to shareholders increased by 9.40% to 1.281 billion CNY [2] - The company has distributed a total of 10.523 billion CNY in dividends since its A-share listing, with 3.721 billion CNY distributed in the last three years [3]

Group 1 - The core viewpoint of the article highlights the growth trends in China's chemical pharmaceutical industry, with a projected production increase in raw chemical drugs by 5.4% in 2025 [1] - According to the National Bureau of Statistics, the production of raw chemical drugs in China reached 333,000 tons in June 2025, reflecting a year-on-year growth of 5.4% [1] - For the first half of 2025, the cumulative production of raw chemical drugs in China was 1.92 million tons, showing a cumulative growth of 4.8% [1] Group 2 - The article lists several publicly listed companies in the pharmaceutical sector, including Heng Rui Medicine, East China Pharmaceutical, and others [1] - It references a report by Zhiyan Consulting that analyzes the supply and demand dynamics of the chemical pharmaceutical industry in China from 2025 to 2031 [1]

Group 1 - The stock price of Lizhu Group is 41.02 yuan, down 0.65% from the previous trading day's closing price [1] - The opening price was 41.35 yuan, with a high of 41.44 yuan and a low of 40.63 yuan, and the trading volume reached 120,447 hands with a transaction amount of 493 million yuan [1] - Lizhu Group operates in the chemical pharmaceutical sector, focusing on the research, production, and sales of pharmaceutical products, including chemical preparations, traditional Chinese medicine preparations, and biological products [1] Group 2 - The latest list of the top ten circulating shareholders shows that the China Europe Medical Health Mixed Fund managed by Ge Lan has become the sixth largest circulating shareholder, holding 5.939 million shares [1] - On August 21, 30 funds participated in a research activity regarding the company, indicating strong interest from institutional investors [1] - Research reports indicate that the company's fundamentals remain stable, with balanced performance across chemical preparations, traditional Chinese medicine, and biological products [1] Group 3 - In terms of capital flow, Lizhu Group saw a net inflow of 44.4728 million yuan from main funds, accounting for 0.19% of the circulating market value [1] - Over the past five days, the cumulative net inflow of main funds was 16.4936 million yuan, representing 0.07% of the circulating market value [1]

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 2. 股份分類 | | 普通股 | 股份類別 A | | 於香港聯交所上市 | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | | | 說明 | 人民幣股份 （於深圳證券交易所主板上市，股份代號：000513) | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | | 2025年8月21日 | 604,293,313 | | | 0 | | 604,293,313 | | 1). 其他 ...

相关事件 格隆汇8月22日丨丽珠医药(01513.HK)公告，8月22日耗资299.6万元回购7.33万股A股。 丽珠医药(01513.HK)8月22日耗资299.6万元回购7.33万股A股 丽珠医药(01513.HK)8月21日耗资300万元 回购7.21万股A股 ...

智通财经APP讯，丽珠医药(01513)发布公告，于2025年8月22日，该公司斥资299.63万元回购7.33万股A 股。 该信息由智通财经网提供 ...

丽珠医药(01513)发布公告，于2025年8月22日，该公司斥资299.63万元回购7.33万股A股。 ...